Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biweekly eribulin mesylate for HER2-negative metastatic breast cancer has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-11-15